Although 131I is an effective therapeutic modality for thyroid cancers that express sodium iodide symporter (NIS), a substantial percentage of metastatic thyroid carcinomas do not express adequate levels of the protein and are categorized as radioiodine refractory thyroid cancers. This evidence concerns the gene SLC5A5 and thyroid cancer.